- Home
- NEGG vs TBPH Comparison
NEGG vs TBPH Comparison
Compare NEGG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | TBPH |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 824.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NEGG | TBPH |
|---|---|---|
| Price | $20.81 | $16.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 75.3K | ★ 301.7K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $9.10 |
| 52 Week High | $137.84 | $21.03 |
Technical Indicators
Market Signals| Indicator | NEGG | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 22.09 | 45.74 |
| Support Level | N/A | $16.14 |
| Resistance Level | $47.10 | $17.21 |
| Average True Range (ATR) | 2.75 | 0.39 |
| MACD | -1.23 | -0.07 |
| Stochastic Oscillator | 0.63 | 11.83 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.